All In Biotech

Drug Trial Radar · NCT07552454

Picankibart in Palmoplantar Pustulosis

Efficacy and Safety of Picankibart in the Treatment of Moderate-to-Severe Palmoplantar Pustulosis: A Prospective, Single-Arm, Open-Label Clinical Study

Last checked: Nov 19, 2026Latest source record: Apr 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Apr 15, 2026

Primary completion

Oct 15, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

1. Study Design This study is designed as a prospective, single-arm, open-label clinical study. It will be conducted by the Department of Dermatology, the First Affiliated Hospital of Air Force Medical University, and plans to enroll 60 eligible subjects. 2. Study Subjects Inclusion Criteria 1. Aged 18-65 years, regardless of gender. 2. Patients with a confirmed diagnosis of palmoplantar pustulosis based on clinical manifestations and/or skin histopathology. 3. Failed treatment with at least one conventional systemic agent (regular administration at standard dosage for 12-24 weeks), or intolerant to adverse reactions. 4. Considered suitable for treatment with Picankibart as assessed by the clinician. 5. Voluntarily participate in the study and provide written informed consent. Exclusion Criteria 1. Patients with active hepatitis B, hepatitis C, or tuberculosis. 2. Pregnant patients or those planning pregnancy within 6 months. 3. Subjects unable to comply with follow-up as required by the study protocol. 4. Other conditions deemed unsuitable for this study. Withdrawal Criteria 1. Subjects may withdraw from the study at any time for any reason. 2. Occurrence of a serious adverse event or intolerable adverse event. 3. Development of any item listed in the exclusion criteria during the study. 4. The investigator may decide subject withdrawal for medical reasons.

Conditions

  • Palmoplantar Pustulosis

Interventions

  • PicankibartDrug

    Induction phase: Picankibart 200 mg administered subcutaneously at Weeks 0, 4, and 8. Maintenance phase: Picankibart 100 mg administered subcutaneously at Weeks 20, 32, and 44.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)Time frame: 16 Week
  2. Change in Palmoplantar Pustular Psoriasis Area and Severity Index (PPPASI)Time frame: 16 Week

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Department of Dermatology, Xijing Hospital, Fourth Military Medical University, No. 127 of West Changle Road, 710032, Xi'an, Shaanxi, China

    Xi'an, Shaanxi, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.